These include the enhanced integration of the Italian MS and Related Disorders (I-MS&RD) Register to support real-world monitoring of therapeutic choices and outcomes, and National efforts to improve access to advanced diagnostic tools—such as volumetric MRI protocols and fluid biomarkers (e.g., serum NfL)—through multicenter collaboration and shared infrastructure. The gene discussed is NEFL; the disease is myeloid sarcoma.